Diabetic microvascular complication
Conditions
Interventions
Diabetes:No intervention
Diabetic retinopathy patients with no intervention:No intervention
Diabetic retinopathy patients with syndrome differentiation-based treatment:syndrome differentiation-based treatment
Diabetic retinopathy patients with stationary treatment:stationary treatment
Diabetic kidney disease patients with no intervention:No intervention
Diabetic kidney disease patientssyndrome differentiation-based treatment :syndrome differentiation-based treatment
Diabetic kidney disease patients stationary treatment:stationary treatment
Sponsors
Chengdu University of T.C.M
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The inclusion criteria of normal person: The health examination shows normal subjects; Age: 18-75; Weight per as body mass index=weight (Kg)/Height (m2), within the range of 19-24; Informed consent, volunteer subjects. 2. The inclusion criteria of 2 diabetes: Conform to type 2 diabetes diagnosis; Age: 18-75; HbA1C=34 scores (ETDRS visual chart, equivalent to Snellen 20/200, decimals 0.1); Subjects with HbA1C=34 scores (ETDRS visual chart, equivalent to Snellen 20/200, decimals 0.1); Subjects with HbA1C300mg/g(> 30mg/mmol)ACR>=30mg/g(3mg/mmol).
Exclusion criteria
Exclusion criteria: 1. Subjects with turbid dioptricmedia that can hardly conduct the eye fundus image evaluation; 2. The examination confirmed that the nephropathy is caused by the primary hypertension or other temic disease. 3. The non-diabetic neuropathies such as cervical & lumbar spondylopathy (radiculopathy, spinal canal stenosis, cervical & lumbar retrogression), cerebral infarction, Guillain-Barre syndrome, serious arteriovenous vascular disease (venous embolism, lymphangitis) etc; 4. Diabetes mellitus combined with lower limbs rupture; 5. The fundus high-risk PDR patients shall conduct the panrentinal photocoagulation immediately; 6. The kidney failure patients shall conduct the dialysis immediately; 7. Subjects who are allergic to the known ingredient of trail drug or the allergic constitution; 8. Combined serious heart disease (chronic heart failure, New York heart function over III, severe ventricular arrhythmias), abnormal liver function (AST, ALT >=twiceper normal limit) as well as severe disease such as hemopoietic tem, psychopath; 9. Patients with serious oculopathy including combined glaucoma, uveitis, age-related macular degeneration optic neuropathy etc; 10. Pregnancy or breast feeding women; 11. Patients with urologic diseases including combined glomerulonephritis, primary nephrotic syndrome, urinary tract infection, obstruction etc; 12. Patients with combined serious infection, diabetic ketoacidosis hyperkalemia; 13. Subjects that had participated in other clinic trails within three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c;Routine blood test;BUN;Crea;Fasting glucose;Routine urine test;ACR;TCM syndrome evaluation;BCVA;CFP;OCT; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT;AST; | — |
Countries
China
Contacts
Public ContactJunguo Duan
Outcome results
None listed